Pediatric neuroblastoma patients without MYCN amplification and with lower E2F3 expression levels had significantly longer event free survival and overall survival in GSE16476, GSE85047 and E-MTAB-1781 datasets (Fig. 6a and supplementary Fig. 3a). This evidence concerns the gene E2F3 and neuroblastoma.